We could not find any results for:
Make sure your spelling is correct or try broadening your search.
uniQure Announces Pricing of its Public Offering LEXINGTON, Mass. and AMSTERDAM, Jan. 08, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing...
uniQure Announces Proposed Public Offering LEXINGTON, Mass. and AMSTERDAM, Jan. 07, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative...
uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease ~ U.S. Food and Drug Administration (FDA) agrees that data from ongoing...
uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy LEXINGTON, Mass. and AMSTERDAM, Nov. 21...
uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress ~ Type B meeting scheduled with the FDA in the fourth quarter of 2024 to initiate discussions...
uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS LEXINGTON, Mass. and AMSTERDAM, Oct. 15, 2024 (GLOBE NEWSWIRE) -- uniQure N.V...
uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease LEXINGTON, Mass. and AMSTERDAM, Sept. 23, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a...
uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease LEXINGTON, Mass. and AMSTERDAM, Aug. 15, 2024 (GLOBE NEWSWIRE) -- uniQure...
uniQure Announces Second Quarter 2024 Financial Results and Provides Company Update ~ Announced RMAT designation for AMT-130 in Huntington’s disease and positive interim Phase I/II data...
uniQure Announces Closing of Sale of Manufacturing Facility to Genezen ~ uniQure maintains preferential access to industry-leading manufacturing capabilities to support its pipeline of gene...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.085 | -0.621118012422 | 13.685 | 14 | 12.605 | 256 | 13.27095628 | DE |
4 | -2.53 | -15.6850588965 | 16.13 | 18.38 | 12.605 | 431 | 16.15892147 | DE |
12 | 7.586 | 126.139008979 | 6.014 | 18.38 | 5.24 | 1652 | 13.25700078 | DE |
26 | 6.648 | 95.6271576525 | 6.952 | 18.38 | 4.11 | 1153 | 11.01398132 | DE |
52 | 8.44 | 163.565891473 | 5.16 | 18.38 | 3.548 | 1253 | 8.66595332 | DE |
156 | -3.42 | -20.0940070505 | 17.02 | 25.61 | 3.548 | 868 | 8.60094039 | DE |
260 | -17.86 | -56.770502225 | 31.46 | 32.78 | 3.548 | 578 | 9.7823537 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions